Percheron Therapeutics (ASX:PER) - Hisse Senedi Fiyatı, Haberler ve Analizler

PER Stoklara Genel Bakış

Percheron Therapeutics Limited, Avustralya'da yeni antisens ilaçların araştırılması ve geliştirilmesiyle ilgilenmektedir. Daha fazla detay

PER temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançların yılda 19.76% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( A$78M )

Anlamlı bir geliri yok ( A$3M )

Son 3 ayda dalgalı hisse senedi fiyatı

Hissedarlar geçen yıl sulandırıldı

Percheron Therapeutics Limited Rakipler

Vitura Health

ASX:VIT

AU$56.4m

Recce Pharmaceuticals

ASX:RCE

AU$109.0m

Starpharma Holdings

ASX:SPL

AU$48.0m

Little Green Pharma

ASX:LGP

AU$39.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Percheron Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.074
52 Haftanın En Yüksek Seviyesi	AU$0.14
52 Haftanın En Düşük Seviyesi	AU$0.052
Beta	0.90
11 Aylık Değişim	-11.90%
3 Aylık Değişim	-7.50%
1 Yıllık Değişim	21.31%
33 Yıllık Değişim	-63.00%
5 Yıllık Değişim	-2.63%
Halka arzdan bu yana değişim	-96.92%

Son Haberler & Güncellemeler

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

Hissedar Getirileri

	PER	AU Pharmaceuticals	AU Pazar
7D	-7.5%	-11.8%	1.5%
1Y	21.3%	39.8%	17.2%

Getiri vs. Endüstri: PER geçen yıl % 39.8 oranında getiri sağlayan Australian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: PER geçen yıl % 17.2 oranında getiri sağlayan Australian Piyasasını aştı.

Fiyat Oynaklığı

Is PER's price volatile compared to industry and market?
PER volatility
PER Average Weekly Movement	13.2%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

İstikrarlı Hisse Senedi Fiyatı: PER hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: PER 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala Australian hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	n/a	James Garner	www.PercheronTx.com

Percheron Therapeutics Limited, Avustralya'da yeni antisens ilaçların araştırılması ve geliştirilmesiyle ilgilenmektedir. Şirketin ürün hattı, Duchenne Musküler Distrofi, Limb Girdle Musküler Distrofi R2, multipl skleroz, astım ve diğer enflamatuar endikasyonların tedavisi için Faz IIa klinik çalışmasında olan bir CD49d antisens inhibitörü olan ATL1102'yi içermektedir. Ürün hattı ayrıca, büyüme hormonu reseptörü ekspresyonunu bloke etmek ve böylece kandaki insülin benzeri büyüme faktörü-I hormonu seviyelerini azaltmak ve Faz II klinik çalışmasını tamamlayan aşırı büyüme hormonu etkisiyle ilişkili hastalıkları tedavi etmek için tasarlanmış büyüme hormonu reseptörünü hedefleyen bir oligonükleotid olan Atesidorsen'i (ATL1103) de içermektedir.

Percheron Therapeutics Limited Temel Bilgiler Özeti

Percheron Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PER temel i̇stati̇sti̇kler
Piyasa değeri	AU$78.44m
Kazançlar(TTM)	-AU$11.92m
Gelir(TTM)	AU$2.97m

26.4x

P/S Oranı

-6.6x

F/K Oranı

PER aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PER gelir tablosu (TTM)
Gelir	AU$2.97m
Gelir Maliyeti	AU$62.15k
Brüt Kâr	AU$2.91m
Diğer Giderler	AU$14.83m
Kazançlar	-AU$11.92m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.011
Brüt Marj	97.91%
Net Kâr Marjı	-401.57%
Borç/Özkaynak Oranı	0%

PER uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PER Stoklara Genel Bakış

Ödüller

Risk Analizi

Percheron Therapeutics Limited Rakipler

ASX:VIT

AU$56.4m

ASX:RCE

AU$109.0m

ASX:SPL

AU$48.0m

ASX:LGP

AU$39.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to AU$0.031 loss

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

New major risk - Financial position

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to AU$0.031 loss

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

New major risk - Financial position

Consensus EPS estimates upgraded to AU$0.034 loss

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?